NR3C1 and breast carcinoma: Therefore, future studies in breast cancer, especially in luminal subtypes, may not only use GR activity as a biomarker but also utilize the new generation of epigenetic inhibitors, applied alone or in combination with standard‐of‐care therapeutics for breast cancer.